Sionna Therapeutics (SION) Retained Earnings (2024 - 2026)

Sionna Therapeutics has disclosed Retained Earnings across 3 years of filings, most recently posting -$283.1 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$283.1 million, down 43.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$283.1 million (down 43.27% YoY), and the FY2025 annual result was -$256.4 million, down 41.56% from the prior year.
• Retained Earnings came in at -$283.1 million for Q1 2026 at Sionna Therapeutics, down from -$256.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$181.1 million in Q4 2024 to a low of -$283.1 million in Q1 2026.
• The 3-year median for Retained Earnings is -$225.8 million (2025), against an average of -$228.3 million.
• Across the five-year window, Retained Earnings plunged 41.56% in 2025 and sank 43.27% in 2026, its largest moves.
• Sionna Therapeutics' Retained Earnings stood at -$181.1 million in 2024, then slumped by 41.56% to -$256.4 million in 2025, then retreated by 10.43% to -$283.1 million in 2026.
• The last three Retained Earnings figures came in at -$283.1 million (Q1 2026), -$256.4 million (Q4 2025), and -$235.9 million (Q3 2025), per Business Quant data.